Nebenwirkungen · Crysvita
CRYSVITA 10 mg solution for injection CRYSVITA 20 mg solution for injection CRYSVITA 30 mg solution for injection CRYSVITA 10 mg solution for injection in pre-filled syringe CRYSVITA 20 mg solution for injection in pre-filled syringe CRYSVITA 30 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 14
HOS-137512 · Präparat HOS-098051
Adult patients with XLH or TIO: Injection site reactions were generally mild in severity, required no treatment, and resolved in almost all instances. In patients with XLH, in the placebo-controlled treatment period of Study UX023-CL303, the frequency of injection site reactions was 12% in both burosumab and placebo treatment groups (injection site reaction, erythema, rash, bruising, pain, pruritus and haematoma). In patients with TIO, the frequency of injection site reactions based on data from completed long term clinical studies was 22% (injection site reaction, injection site pain and injection site swelling).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-10T15:55:00Z · SHA-256 baf321a382cbdfea294d2bc7e1ecf474206ad3f46c5ad10e5282c77941e72d66 · Passage bd994a4f5b8000e3d0d69fac0b869722da5c4977714a506006ae4f93d662bbeb · Zeichen 11115–11736 im Abschnitt